Impel Pharmaceuticals
Information
Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. TRUDHESA™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) is now approved for the acute treatment of migraine with or without aura in adults. TRUDHESA was previously known as INP104.